deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT01526928

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral Rociletinib in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Clovis Oncology, Inc.

Conditions Locally Advanced or Metastatic Non Small Cell Lung Cancer
Interventions Rociletinib
Updated 13 times since 2017 Last updated: Jul 26, 2020 Started: Mar 27, 2012 Primary completion: Jul 3, 2018 Completion: Aug 27, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Clovis Oncology, Inc.

More terminations from Clovis Oncology, Inc.

This PHASE1/PHASE2 trial investigates Locally Advanced or Metastatic Non Small Cell Lung Cancer and is currently terminated or withdrawn. Clovis Oncology, Inc. leads this study, which shows 13 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~May 2019 · 7 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  5. Sep 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Feb 2020 — Sep 2020 [monthly]

    Terminated PHASE1_PHASE2

    Status: Completed → Terminated

  2. Jun 2019 — Feb 2020 [monthly]

    Completed PHASE1_PHASE2

  3. May 2019 — Jun 2019 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  4. Oct 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Unknown Status → Active Not Recruiting

  5. Aug 2018 — Oct 2018 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Active Not Recruiting → Unknown Status

  6. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Clovis Oncology, Inc.
Data source: Clovis Oncology, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Athens, United States , Aurora, United States , Baltimore, United States , Boston, United States , Buffalo, United States , Caen, France , Camperdown, Australia , Chicago, United States , Cincinnati, United States and 35 more locations